U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Meta Expands AI Training With Employee Activity Tracking Tools 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
ST. LOUIS, May 19, 2017 -- GeneriCo, LLC (GeneriCo), a global specialty generic drug company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review (“IPR”) of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688 (the ‘688 Patent). The PTAB’s decision invalidates all of the disputed claims of the '688 Patent that previously provided Apriso® (extended-release capsules containing 0.375g mesalamine as a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults) FDA Orange Book exclusivity through May 1, 2030.
“Along with our IPR partner Flat Line Capital, LLC, we are pleased that the PTAB has decided to invalidate all the disputed claims of the ‘688 Patent,” said Daniel Thompson, GeneriCo President and CEO. “While more remains to be done, this is a significant step forward to lowering prescription drug costs for patients and healthcare providers in the U.S. system.”
Kevin Barnes, Principal of Flat Line Capital, LLC added, “We believe this successful IPR outcome further validates our leadership in pharmaceutical intellectual property disputes and the effectiveness of our platform.”
About GeneriCo, LLC
GeneriCo, LLC is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the United States. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in 2017.
Contact: Daniel Thompson, President and CEO Phone Number: 1.314.330.0800 Email: [email protected] www.genericopharma.com
